Mozi

Mozi is a biotechnology company leveraging generative artificial intelligence to revolutionize protein engineering and drug discovery. The company's platform focuses on the de novo design of functional proteins, including antibodies and enzymes, to address complex therapeutic challenges. By integrating advanced machine learning models with high-throughput experimental validation, Mozi aims to significantly accelerate the development of next-generation biologics. The company is positioned at the intersection of deep learning and molecular biology, seeking to create optimized therapeutic candidates with enhanced specificity and efficacy. Mozi's approach represents a shift toward programmable biology, where proteins can be designed for specific functions from first principles.